Back to results
US 2004/0176272 A1Published application
Uses of integrin alphavbeta3 antagonists
AssigneeMedImmune, LLC
InventorsRonald L. Wilder, Su-Yau Mao
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeMedImmune, LLC
InventorsRonald L. Wilder, Su-Yau Mao
Estimating the term…
The present invention provides methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing antagonists of integrin αvβ3. The present invention encompasses the use of methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy, or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing an integrin αvβ3 antagonist in combination with another therapy (e.g., another prophylactic or therapeutic agent). In particular, the present invention provides methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, comprising administering to a subject in need thereof at least one antagonist of integrin αvβ3 and at least one other therapy. The present invention encompasses compositions and articles of manufacture for use in preventing, treating, managing or ameliorating periodontal disease, or aseptic loosening of joint replacement (prostheses), Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or conditions associated therewith.
A method of treating, managing or ameliorating a disease or a symptom or condition associated therewith, said method comprising administering to a subject in need thereof an effective amount of an integrin αvβ3 antagonist, wherein the disease is aseptic loosening of a joint replacement, periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, or hypertrophic pulmonary osteoarthropathy.
A method of treating, managing or ameliorating a disease or a symptom or condition associated therewith, said method comprising the steps of:
An article of manufacture comprising packaging material, instructions, and a pharmaceutical composition in suitable form for administration to a human, contained within said packaging material, wherein said pharmaceutical composition comprises an integrin αvβ3 antagonist and a pharmaceutically acceptable carrier, and said instructions suggest a dosing regimen for the prevention, treatment, management, or amelioration of a disease or a symptom or condition associated therewith, wherein the disease is aseptic loosening of a joint replacement, periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, or hypertrophic pulmonary osteoarthropathy.
An article of manufacture comprising packaging material, instructions, and two pharmaceutical compositions in suitable form for administration to a human contained within said packaging material, wherein the first pharmaceutical composition comprises an integrin αvβ3 antagonist and a pharmaceutically acceptable carrier, and the second pharmaceutical composition comprises a prophylactic or therapeutic agent other than an integrin αvβ3 antagonist and a pharmaceutically acceptable carrier, and said instructions suggest a dosing regimen for the prevention, treatment, management, or amelioration of a disease or a symptom or condition associated therewith, wherein the disease is aseptic loosening of a joint replacement, periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, or hypertrophic pulmonary osteoarthropathy.
Dependencies are inferred from the claim text.